All News

The approval of flotufolastat F 18 (formerly 18F-rhPSMA-7.3) in prostate cancer is based on findings from the phase 3 SPOTLIGHT and LIGHTHOUSE trials.

The study assessed US veterans receiving care at the Veterans Health Administration for all cancer types, including prostate cancer.

Social Security benefits aren’t sufficient to fund retirement for most people. And given the aging of the population and projected trust-fund shortfall, they may be less generous in the future.

The study assessed 120 women with overactive bladder for associations between anxiety and somatic symptoms, quality of life, quantitative sensory testing measures, and psychological stress symptoms.

“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.

The intravesical drug delivery system TAR-210 is designed to provide localized continuous release of erdafitinib in patients with bladder cancer.

Patients classified as GC high risk had a 5-year disease progression of 40%, compared with 20% among GC low-risk patients.

The 5-year metastasis-free survival rate was 75% with trimodality therapy vs 74% with radical cystectomy.

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

The theranostic 64Cu/67Cu SAR-bisPSMA yielded positive safety and efficacy signals in patients with metastatic castration-resistant prostate cancer.

"We believe that more thorough body weight control in childhood could serve as a preventive measure for preserving testicular function in adulthood," says Rosella Cannarella, MD, PhD.

"At 1 month, there was a clinically significant improvement in SHIM scoring in men that did receive the treatment vs the sham arm, which didn't," says Jeunice Owens-Walton, MD.

The trial assessed outcomes in patients who had kidney stones between 1 to 2 cm.

"I’m frank with them. If it’s something I haven’t heard of, I tell them. I also tell them where I get my information," says Kevin Krughoff, MD.

The data were presented at the recent American Urological Association Annual Meeting.

Trajectory inference analysis pointed to SIX2+CITED1+ as the nephrogenic cancer stem cells at the origin of Wilms tumor.

While online reviews are critical in any industry, patient expectations are simply different when it comes to health care.

“These results validate the clinical value of bone biomarker assessment in the HSPC state," state the authors.

Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery.

Bradley Gill, MD, MS, recaps several presentations on benign prostatic hyperplasia from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

"A couple [of] times recently, I’ve done 6 in 1 day. A couple weeks ago, I did 4, the week before that, 5. So I would say I’ve seen an uptick," says urologist Bradford Black, MD.

The findings held even when the investigators adjusted for age, past medical history, smoking status, and type of surgery.

Katie S. Murray, DO, recaps several presentations on bladder cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

Kelly L. Stratton, MD, FACS, recaps several presentations on prostate cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

The study also found a positive correlation between burnout and discrimination-based trauma in trainees.

Here’s how the specialty fared vs other eligible clinicians.

Implementing the right practice technology can not only mitigate physician burnout, it can also enable patients to take charge of their own care experience.

Jen-Jane Liu, MD, discusses how PSMA-PET imaging might help physicians decide whether or not a patient with prostate cancer needs lymph node dissection.